Piscataway, NJ, United States of America

Brent Whitehead

USPTO Granted Patents = 13 (Patent Applications = 1)

CIPO Patents = 1

EPO Patents = 4 (Patent Applications = 2)

Average Co-Inventor Count = 7.2

ph-index = 1

Forward Citations = 3(Granted Patents)

Location History:

Piscataway, NJ (US) (2011 - 2014)
Morristown, NJ (US) (2013 - 2021)

Company Filing History:

9 out of 2,405

Merck Sharp + Dohme Corp.

patents

4 out of 1,086

Bausch & Lomb Incorporated

patents

Years Active: 2011-2021

Loading Chart...

13 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11046714 - 2,2-difluorodioxolo Areceptor antagonists (2021-06-29),

2. 11014920 - Factor XIIa inhibitors (2021-05-25),

3. 10875851 - Factor XIIa inhibitors (2020-12-29),

4. 9518055 - Imidazopyridyl compounds as aldosterone synthase inhibitors (2016-12-13),

5. 9108920 - Diazeniumdiolate heterocyclic derivatives (2015-08-18),

6. 8637515 - Polymorphs of brimonidine pamoate (2014-01-28),

7. 8637514 - Polymorphs of brimonidine pamoate (2014-01-28),

8. 8530521 - Nitrooxy cycloalkane derivatives (2013-09-10),

9. 8420648 - Polymorphs of brimonidine pamoate (2013-04-16),

10. 8361994 - Primary amine diazeniumdiolate heterocyclic derivatives (2013-01-29),

11. 8053455 - Angiotensin II receptor antagonists (2011-11-08),

12. 8034813 - Polymorphs of brimonidine pamoate (2011-10-11),

13. 7947664 - Angiotensin II receptor antagonists (2011-05-24),

Title: Brent Whitehead: Innovator in Pharmaceutical Compounds

Introduction

Brent Whitehead is a notable inventor based in Piscataway, NJ (US), recognized for his contributions to the field of pharmaceuticals. With a total of 13 patents to his name, he has made significant advancements in the development of compounds aimed at treating various medical conditions.

Latest Patents

Among his latest innovations are the patents for 2,2-difluorodioxolo Areceptor antagonists and Factor XIIa inhibitors. The 2,2-difluorodioxolo compounds serve as antagonists of Areceptor, with potential applications in the treatment or prevention of neurological disorders. Additionally, these compounds are formulated into pharmaceutical compositions for effective use against diseases involving Areceptors. The Factor XIIa inhibitors, on the other hand, provide a selective approach to treating or preventing thromboses, embolisms, hypercoagulability, or fibrotic changes, showcasing Brent's commitment to addressing critical health issues.

Career Highlights

Brent has worked with prominent companies such as Merck Sharp & Dohme Corporation and Bausch & Lomb Incorporated. His experience in these organizations has contributed to his expertise in pharmaceutical research and development.

Collaborations

Throughout his career, Brent has collaborated with talented individuals, including Amjad Ali and Michael Man-Chu Lo. These partnerships have likely enhanced his innovative capabilities and broadened the impact of his work.

Conclusion

Brent Whitehead stands out as a significant figure in the pharmaceutical industry, with a focus on developing innovative compounds for critical health challenges. His contributions continue to influence the field and pave the way for future advancements.

This text is generated by artificial intelligence and may not be accurate.